No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NVS Novartis AG
- 97.440
- -1.620-1.64%
Close Apr 26 16:00 ET
- 97.000
- -0.440-0.45%
Post 18:14 ET
198.82BMarket Cap13.29P/E (TTM)
98.220High97.440Low1.56MVolume97.760Open99.060Pre Close152.82MTurnover0.08%Turnover Ratio13.72P/E (Static)2.04BShares104.81652wk High5.01P/B189.92BFloat Cap85.72652wk Low3.78Dividend TTM1.95BShs Float104.816Historical High3.88%Div YieldTTM0.79%Amplitude7.088Historical Low97.782Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Express News | Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 18.83% BMO Capital $114 → $116 Maintains Market Perform 02/23/2024 16.78% BMO Capital → $114 In
Company News for Apr 24, 2024
Express News | Novartis AG : BMO Raises Target Price to $116 From $114
Express News | Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Comments
What Happened Last Trade Day (Mar 15)
Stories you might have missed 
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
M&A Update
Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
1
ColumnsBiotech M&A Frenzy: Is the Industry Poised for a Promising Recovery in 2024?
Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
●$Johnson & Johnson(JNJ.US$ has agreed to pay $2 billion in cash for antib...
●$Johnson & Johnson(JNJ.US$ has agreed to pay $2 billion in cash for antib...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
